CD274 and non-small cell lung carcinoma: That study reported that in patients receiving first-line therapy for NSCLC with high TMB, PFS was longer with nivolumab plus ipilimumab than with chemotherapy irrespective of PD-L1 levels (7.2 months vs 5.5 months; hazard ratio for disease progression or death [95% CI]: 0.58 [0.41 to 0.81]).